Retatrutide Pre-Mixed Research Pen - 40mg

RETATRUTIDE is a potent triple agonist (GLP-1, GIP, GCGR) designed for weekly administration. Clinical data indicate up to a 24% reduction in body weight after 48 weeks and an 82% decrease in liver fat, making it one of the most effective peptides studied for obesity and metabolic health.

RETATRUTIDE is a synthetic multireceptor agonist designed to coordinate satiety signalling, glucose management, and energy expenditure by simultaneously activating GLP-1R, GIPR, and GCGR. In research models, this triad produces significant weight loss, improves glycaemic parameters and lipid oxidation, offering a comprehensive platform for studying body metabolic remodeling. Research use only: Intended for controlled protocols, not for human consumption. Formulated in a stabilized pre-mixed injection pen. Intended exclusively for laboratory and research use. 

• Benefits:

§  Triple agonist mechanism for comprehensive metabolic regulation:
RETATRUTIDE is a potent agonist of GLP-1, GIP and glucagon receptors, studied for its multipathway activation of energy metabolism. By interacting with all three receptors, it improves insulin secretion, suppresses appetite, and simultaneously promotes lipid oxidation. This triple-agonist design provides broader metabolic modulation than single or dual incretin analogues, making it a key topic in next-generation obesity and diabetes research.

§  Exceptional Weight Loss Results:
Clinical and preclinical data demonstrate that RETATRUTIDE can produce a body weight reduction of up to 24% over extended treatment periods. This result exceeds that of previous GLP-1 or GLP-1/GIP agonists thanks to the improvement of the mechanisms of thermogenesis and fat oxidation. Research indicates a sustained and progressive decrease in subcutaneous and visceral fat mass, which positions RETATRUTIDE as a new benchmark in metabolic optimization studies.

§  Marked reduction in visceral and hepatic fat:
RETATRUTIDE has been observed to dramatically reduce liver fat content (more than 80% according to clinical data) and visceral adiposity in both obese subjects and those with type 2 diabetes. This effect is due to its ability to activate glucagon receptor-mediated lipid metabolism and improve mitochondrial β-oxidation, which promotes better liver function and systemic metabolic balance.

§  Improved glucose control and insulin sensitivity:
By simultaneously activating the incretinic pathways, RETATRUTIDE improves insulin secretion, suppresses glucagon, and improves peripheral glucose uptake. This coordinated metabolic effect results in a significant reduction in HbA1c and stabilization of fasting glucose levels in research subjects. These findings highlight its potential as one of the most effective hypoglycemic peptides in research.

§  Improved lipid profile and cardiovascular markers:
Administration of RETATRUTIDE has been associated with improved lipid metabolism, including reductions in total cholesterol, LDL, and triglycerides. Studies also report a decrease in systolic blood pressure and inflammatory markers such as CRP, suggesting favourable cardiometabolic outcomes in long-term metabolic studies.

§  Stimulation of energy expenditure and thermogenesis:
In animal models, retatrutide increases the thermogenic activity of brown adipose tissue through glucagon receptor signaling, leading to increased resting energy expenditure. Improved mitochondrial respiration and fatty acid oxidation contribute to continued fat loss, even with moderate caloric intake, demonstrating its potential as a metabolism booster in research applications.

§  Reduction of systemic inflammation:
RETATRUTIDE has been observed to reduce inflammatory cytokines such as TNF-α and IL-6, while improving endothelial function and vascular elasticity. These anti-inflammatory and vasoprotective effects complement their metabolic actions, promoting greater cardiovascular resilience in experimental models of metabolic diseases.

§  Preservation of lean body mass:
Research results suggest that, despite substantial fat loss, RETATRUTIDE supports the maintenance of lean muscle tissue. This balance between fat reduction and muscle preservation reflects its unique energy-sharing effect, making it valuable for studies exploring body recomposition and improving athletic performance.

§  Improved liver function and NAFLD:
Initial preclinical and clinical studies show significant improvements in non-alcoholic fatty liver disease (NAFLD) parameters, including a reduction in liver inflammation and fibrosis. Activation of the RETATRUTIDE triple agonist enhances AMPK signaling, which reduces lipid accumulation and promotes liver regeneration in hepatic metabolic research.

§  Synergistic effects with GLP-1 and mitochondrial peptides:
Experimental protocols combining RETATRUTIDE with SEMAGLUTIDE, MOTS-c, or SS-31 to improve mitochondrial bioenergetics, lipid metabolism, and overall metabolic performance are being explored. These combined combinations seek to maximize fat oxidation, reduce inflammation, and maintain high energy efficiency in long-term research models.

§  Long-term metabolic adaptation and weight maintenance:
Follow-up studies indicate that subjects maintained more than 80% of their weight loss after long periods of observation, even after discontinuation of treatment. This sustained adaptation reflects lasting improvements in metabolic set point, appetite control, and mitochondrial efficiency, positioning RETATRUTIDE as a very promising agent for advanced metabolic research.

Pre-Mixed Cartridge and Kit:

• 1 x Cartridge
• 1 x Peptide Cartridge Pen
• 1 x Pen Carry Case
• 8 x Pen Needle Tips

Single Mixed Cartridges (1,2 & 3) Come with:

• 1,2 or 3 x Cartridge (The cartridge is premixed with the peptide vial of your choice and Bacteriostatic Water)
• 8 x Pen Needle Tips

The single 1,2 & 3 cartridges do not come with a kit.

Handling and Storage:

• Store this product in a dry place, away from sunlight and moisture
• Keep each unit sealed when not in use
• Store at 2-8 °C to minimise freeze thaw, prepare aliquots according to your protocol
• 4 x Use only within research protocols that follow your lab’s SOPs and local regulations

For Research Use Only

This product is supplied strictly for scientific research and laboratory experimentation. It is not intended for human consumption, clinical use or any form of therapeutic application.